Peptide-based tumor-associated antigen vaccine in glioblastoma: Correlative results of the ETAPA Phase I clinical trial
Immunotherapy has yet to yield benefit in glioblastoma (GBM), in part due to inadequate T-cell priming and insufficient CD4+ helper support. To enhance coordinated CD4+ and CD8+ activation, the ETAPA phase 1 trial (NCT05283109) evaluated P30-EPS, a peptide vaccine linking three class I tumor-associated antigens (CMV pp65, Survivin, EphA2) to the universal class II tetanus toxoid epitope P30…
